Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer

Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton‐interfering pharmacophores, in testicular...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinemann, Gustav, Dittmer, Alexandra, Schmidt, Jacob, Josuttis, David, Fähling, Michael, Biersack, Bernhard, Beindorff, Nicola, Jolante Koziolek, Eva, Schobert, Rainer, Brenner, Winfried, Müller, Thomas, Nitzsche, Bianca, Höpfner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887589/
https://www.ncbi.nlm.nih.gov/pubmed/31583820
http://dx.doi.org/10.1002/1878-0261.12582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887589/
https://www.ncbi.nlm.nih.gov/pubmed/31583820
http://dx.doi.org/10.1002/1878-0261.12582

Ejemplares similares